Catalyst Biosciences Stock Price To Earnings To Growth
CBIODelisted Stock | USD 0.41 0.02 4.65% |
Catalyst Biosciences fundamentals help investors to digest information that contributes to Catalyst Biosciences' financial success or failures. It also enables traders to predict the movement of Catalyst Stock. The fundamental analysis module provides a way to measure Catalyst Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Catalyst Biosciences stock.
Catalyst |
Catalyst Biosciences Company Price To Earnings To Growth Analysis
Catalyst Biosciences' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Catalyst Biosciences Price To Earnings To Growth | 0.02 X |
Most of Catalyst Biosciences' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Catalyst Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Catalyst Biosciences has a Price To Earnings To Growth of 0.02 times. This is 97.18% lower than that of the Biotechnology sector and 99.36% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 99.59% higher than that of the company.
Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
All Next | Launch Module |
Catalyst Fundamentals
Return On Equity | -2.69 | |||
Return On Asset | -0.38 | |||
Current Valuation | 51.03 M | |||
Shares Outstanding | 37.97 M | |||
Shares Owned By Insiders | 27.73 % | |||
Shares Owned By Institutions | 8.75 % | |||
Number Of Shares Shorted | 34.05 K | |||
Price To Earning | (0.34) X | |||
Price To Book | 0.53 X | |||
Price To Sales | 4.82 X | |||
Revenue | 794 K | |||
Gross Profit | (64.91 M) | |||
EBITDA | (52.15 M) | |||
Net Income | (8.24 M) | |||
Cash And Equivalents | 75.39 M | |||
Cash Per Share | 2.39 X | |||
Total Debt | 38 K | |||
Debt To Equity | 0.02 % | |||
Current Ratio | 18.86 X | |||
Book Value Per Share | (0.78) X | |||
Cash Flow From Operations | (33.1 M) | |||
Short Ratio | 0.19 X | |||
Earnings Per Share | (1.50) X | |||
Price To Earnings To Growth | 0.02 X | |||
Target Price | 16.0 | |||
Beta | 1.29 | |||
Market Capitalization | 19.37 M | |||
Total Asset | 28.44 M | |||
Retained Earnings | (410.94 M) | |||
Working Capital | 11.38 M | |||
Current Asset | 68.7 M | |||
Current Liabilities | 37.76 M | |||
Annual Yield | 7.93 % | |||
Net Asset | 28.44 M |
About Catalyst Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Catalyst Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalyst Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalyst Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Catalyst Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Catalyst Stock
0.9 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
0.87 | HPQ | HP Inc | PairCorr |
0.82 | KEP | Korea Electric Power | PairCorr |
0.81 | SHG | Shinhan Financial | PairCorr |
0.81 | WF | Woori Financial Group | PairCorr |
The ability to find closely correlated positions to Catalyst Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Biosciences to buy it.
The correlation of Catalyst Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalyst Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Catalyst Stock
If you are still planning to invest in Catalyst Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalyst Biosciences' history and understand the potential risks before investing.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |